'Nt probnp' presentation slideshows

Top Clinical Issues

Top Clinical Issues. Eltanya A. Patterson, MD. Heart Failure Guidelines. Eltanya A. Patterson, MD. Definition. Complex clinical syndrome Any structural or functional impairment of ventricular filling or ejection of blood Cardinal s/ sx Dyspnea and fatigue Fluid retention

1.13k views • 97 slides

October 2016

CCS 2016 Guideline: Perioperative Cardiac Risk Assessment and Management for Patients Undergoing Non-Cardiac Surgery. October 2016. Disclosures. All CCS guideline and position statement panel conflicts of interest can be found on the CCS website ( www.ccs.ca ).

1.72k views • 96 slides

622 views • 50 slides

Lower Limb Amputation Surgery and Rehabilitation (Lessons from ISPO Workshop in Bangkok 2009)

768 views • 42 slides

Disclosures

Benefits of Natriuretic Peptide Guided Heart Failure Therapy for Patients With Chronic Left Ventricular Systolic Dysfunction Results of the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.

550 views • 37 slides

432 views • 32 slides

NorthStar :

NT-proBNP stratified follow up in outpatients heart failure clinics : A Randomized Danish Multicenter Study. NorthStar :. Morten Schou, MD, PhD Principal Investigator Hillerod University Hospital, Copenhagen The Danish Heart Failure Clinics Network

488 views • 29 slides

I-PRESERVE Trial Irbesartan in heart failure with preserved EF

I-PRESERVE Trial Irbesartan in heart failure with preserved EF. Executive Committee M. Komajda, R. McKelvie, J. McMurray, M. Zile, C. Staiger, A. Ptaszynska. Co-PIs: Peter Carson and Barry Massie. On behalf of the I-PRESERVE Investigators and Patients. Presenter Disclosure Information.

577 views • 24 slides

478 views • 23 slides

Good use of biotests in emergency

Good use of biotests in emergency. Dr. David Tran FVHospital 28 April 2010. Interest of a biotest. Can help the clinician to confirm or rule out a diagnosis (troponine, lipase, AgNS1, d.dimeres)

354 views • 22 slides

How can new diagnostic methods contribute in healthcare ? What are doctors looking for?

How can new diagnostic methods contribute in healthcare ? What are doctors looking for?. Better support in their clinical decision makings, which includes: more accurate diagnosis reliable prognostic estimation tools for therapy stratification and monitoring

301 views • 17 slides

277 views • 15 slides

Ozsu S * , Karaman K ** ,Mentese A *** ,Ozsu A **** , Karahan C *** , * Ozlu T

Right ventricular dysfunction and biomarkers: Risk stratification in normotensive patients with pulmonary embolism. Ozsu S * , Karaman K ** ,Mentese A *** ,Ozsu A **** , Karahan C *** , * Ozlu T .Karadeniz Technical University, * Department of Chest Disease ,

263 views • 14 slides

British Heart Valve Society Carcinoid Heart Disease

British Heart Valve Society Carcinoid Heart Disease. Dr C Hayward MB BChir MRCP , Dr S Bhattacharyya MD MRCP, Dr J Davar MD PhD Royal Free Hospital, London, UK. Case Presentation. Clinical History 60 year old female.

547 views • 12 slides

Background & Objectives

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial.

175 views • 10 slides

Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) Quartile*. Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176.

177 views • 7 slides

Anwaruddin S et al. J Am Coll Cardiol 2005; available at sciencedirect.

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival. NT-proBNP=N-terminal brain-type natriuretic peptide GFR=glomerular filtration rate. Anwaruddin S et al. J Am Coll Cardiol 2005; available at http://www.sciencedirect.com.

131 views • 2 slides

GRACE

predicted. predicted. predicted. observed. observed. observed. Supplementary figure. A. B. C. GRACE. GRACE + NT-proBNP. GRACE + GDF-15. 0.25. 0.25. 0.25. 0.20. 0.20. 0.20. Risk of 6 month death or MI. 0.15. 0.15. 0.15. 0.10. 0.10. 0.10. 0.05. 0.05. 0.05. 0. 0. 0.

272 views • 1 slides

Patients 3-10 days post ACS without HF/LVSD but ? natriuretic peptides

N=1101. Patients 3-10 days post ACS without HF/LVSD but ? natriuretic peptides. Standard Medical Therapy. NT- proBNP & Aldosterone. Blinded Therapy. Placebo. Aliskiren. Valsartan. Valsartan /Aliskiren. 4 wks. Dose up-titration over 2 weeks. NT-proBNP.

120 views • 1 slides

Background

The Value of NT-proBNP for the Evaluation of Acute CHF: A Multi-center, International Pooled Analysis of 1256 Subjects: Primary Results from the I nternational C ollaborative o f N T-proBNP (ICON) Study

180 views • 1 slides